Orphan drug: Difference between revisions

Latest revision as of 12:09, 15 February 2025

Overview of orphan drugs in medicine

Overview[edit]

An orphan drug is a pharmaceutical agent developed specifically to treat a rare medical condition, often referred to as an orphan disease. These conditions are so rare that there is little financial incentive for the private sector to develop and market treatments. The designation of a drug as an orphan drug is intended to encourage the development of medications for these rare diseases.

Orphan Drug Act[edit]

The Orphan Drug Act was passed in the United States in 1983 to facilitate the development of orphan drugs. This legislation provides incentives such as tax credits, grant funding, and market exclusivity to encourage pharmaceutical companies to develop treatments for rare diseases. Similar legislation exists in other regions, such as the European Union and Japan.

Development Challenges[edit]

Developing orphan drugs presents unique challenges. The small patient populations make it difficult to conduct large-scale clinical trials, and the limited market potential can deter investment. However, the incentives provided by orphan drug legislation aim to mitigate these challenges.

Examples of Orphan Drugs[edit]

Many orphan drugs have been developed to treat a variety of rare conditions. Some notable examples include:

Imatinib, used to treat certain types of leukemia.
Ivacaftor, used for treating specific mutations in cystic fibrosis.
Eculizumab, used for treating paroxysmal nocturnal hemoglobinuria.

Rosuvastatin[edit]

While not an orphan drug, Rosuvastatin is a widely used statin for lowering cholesterol and preventing cardiovascular disease. It is included here to illustrate the difference between common medications and those developed for rare conditions.

Regulatory Framework[edit]

The regulatory framework for orphan drugs varies by country but generally includes provisions for:

Market exclusivity for a certain period after approval.
Assistance with the drug approval process.
Financial incentives such as tax credits and grants.

Impact on Patients[edit]

Orphan drugs have a significant impact on patients with rare diseases, providing treatment options where none previously existed. The development of these drugs can improve quality of life and, in some cases, extend life expectancy.

Related pages[edit]

@@ Line 1: / Line 1: @@
-An '''Orphan Drug''' refers to a pharmaceutical agent developed specifically to treat, diagnose, or prevent diseases that are so rare they are often overlooked by the mainstream pharmaceutical industry. The United States Food and Drug Administration (FDA) grants Orphan Drug designation to encourage development of treatments for diseases affecting fewer than 200,000 individuals in the country.
+{{Short description|Overview of orphan drugs in medicine}}
+{{Use dmy dates|date=October 2023}}
-=== History ===
+==Overview==
-The concept of orphan drugs arose in the 1980s, with the United States Congress passing the Orphan Drug Act (ODA) in 1983. This legislation was created to address the need for drugs for rare diseases, which were not being adequately developed by the pharmaceutical industry due to the limited potential for profitability.
+An '''orphan drug''' is a pharmaceutical agent developed specifically to treat a rare medical condition, often referred to as an [[orphan disease]]. These conditions are so rare that there is little financial incentive for the private sector to develop and market treatments. The designation of a drug as an orphan drug is intended to encourage the development of medications for these rare diseases.
-=== Orphan Drug Designation ===
+==Orphan Drug Act==
-The FDA's Orphan Drug Designation program provides various incentives for drug developers, including tax credits for clinical trial costs, assistance in the drug development process, and exclusive marketing rights upon approval.
+The [[Orphan Drug Act]] was passed in the United States in 1983 to facilitate the development of orphan drugs. This legislation provides incentives such as tax credits, grant funding, and market exclusivity to encourage pharmaceutical companies to develop treatments for rare diseases. Similar legislation exists in other regions, such as the European Union and Japan.
-=== Global Impact ===
+==Development Challenges==
-Following the success of the ODA in the United States, similar regulatory frameworks have been established worldwide, including in Europe under the European Medicines Agency (EMA) and in Japan through the Ministry of Health, Labour, and Welfare.
+Developing orphan drugs presents unique challenges. The small patient populations make it difficult to conduct large-scale [[clinical trials]], and the limited market potential can deter investment. However, the incentives provided by orphan drug legislation aim to mitigate these challenges.
-=== Challenges and Controversies ===
+==Examples of Orphan Drugs==
-While the Orphan Drug Act has significantly boosted the development of treatments for rare diseases, it has also faced criticism. Concerns include high prices of orphan drugs and companies exploiting the system for financial gain.
+Many orphan drugs have been developed to treat a variety of rare conditions. Some notable examples include:
+* [[Imatinib]], used to treat certain types of [[leukemia]].
+* [[Ivacaftor]], used for treating specific mutations in [[cystic fibrosis]].
+* [[Eculizumab]], used for treating [[paroxysmal nocturnal hemoglobinuria]].
-==Orphan disease==
+==Rosuvastatin==
-An orphan disease is a rare disease or condition that affects fewer than 200,000 people in the United States.
+[[File:Rosuvastatin_structure.svg|thumb|right|Chemical structure of Rosuvastatin]]
+While not an orphan drug, [[Rosuvastatin]] is a widely used [[statin]] for lowering cholesterol and preventing cardiovascular disease. It is included here to illustrate the difference between common medications and those developed for rare conditions.
-==Importance==
+==Regulatory Framework==
-Orphan diseases are often serious or life threatening.
+The regulatory framework for orphan drugs varies by country but generally includes provisions for:
+* Market exclusivity for a certain period after approval.
+* Assistance with the drug approval process.
+* Financial incentives such as tax credits and grants.
-==US law==
+==Impact on Patients==
-In 1983, the U.S. government passed a law, called the [[Orphan Drug Act]], to give drug companies certain financial benefits for developing orphan drugs that are safe and effective.
+Orphan drugs have a significant impact on patients with rare diseases, providing treatment options where none previously existed. The development of these drugs can improve quality of life and, in some cases, extend life expectancy.
-== Glossary ==
+==Related pages==
-* '''[[Orphan disease]]''' - A disease that affects a small percentage of the population, often lacking sufficient drug development under normal market conditions due to a small potential market.
+* [[Orphan disease]]
-* '''[[Food and Drug Administration (FDA)]]''' - The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices in the United States.
+* [[Pharmaceutical industry]]
-* '''[[European Medicines Agency (EMA)]]''' - An agency of the European Union (EU) responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the EU.
+* [[Drug development]]
-* '''[[Clinical trials]]''' - Research studies performed on human volunteers designed to answer specific health questions, including testing the efficacy and safety of new treatments.
+* [[Clinical trial]]
-* '''[[Market exclusivity]]''' - A period during which the FDA promises not to approve generic versions of an orphan drug, typically lasting 7 years in the United States, to encourage development.
-* '''[[Rare disease]]''' - A condition affecting a small portion of the population, defined in the U.S. as affecting fewer than 200,000 people nationwide.
+[[Category:Pharmaceuticals]]
-* '''[[Tax credits]]''' - Part of the incentives provided under the Orphan Drug Act, allowing companies to reduce their tax liability as a reward for conducting qualified clinical trials.
+[[Category:Drug development]]
-* '''[[Regulatory framework]]''' - The system of regulations and guidelines that govern the development, approval, and marketing of drugs and therapies.
+[[Category:Orphan drugs]]
-* '''[[Pharmaceutical industry]]''' - The sector of the health care industry that deals with the development, production, and marketing of medications.
-* '''[[Drug development]]''' - The process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.
-== Also see ==
-* [[List of orphan drugs]]
-{{orphan drugs}}
-{{stub}}
-{{DEFAULTSORT:Orphan Drug}}
-[[Category:Orphan drugs| ]]
-[[Category:Biotechnology law]]
-[[Category:Drug discovery]]
-[[Category:Pharmaceuticals policy]]
-[[Category:Health economics]]
-[[Category:Life sciences industry]]
-[[Category:Rare diseases]]